EQS-News: RELIEF THERAPEUTICS Holding AG: Reliefs Partner Acer Therapeutics plant nach vorbereitendem Treffen mit der FDA die Einreichung des Zulassungsantrags für ACER-001 in Q3 2021
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
EQS-News: RELIEF THERAPEUTICS Holding AG: Relief gibt Update zu Fortschritten und Plänen mit ACER-001 zur Behandlung von Harnstoffzyklusstörungen
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B V as Manufacturing and Supply Chain Consultant
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Relief Therapeutics Holding AG: Relief Engages Jan-Jaap Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant
Relief or the
Company ), a biopharmaceutical company with its lead compound RLF-100
TM (aviptadil) in advanced clinical development to treat COVID-19 induced respiratory disorders, today announced the appointment of J.J. Scherpbier of Sonsbeek Pharma Consultancy B.V. as Manufacturing and Supply Chain Consultant effective April 01, 2021. Mr. Scherpbier will support the Relief management team in all activities pertaining to manufacturing and supply projects across the Company s portfolio. Mr. Scherpbier will initially focus on the establishment of a supply chain in the Relief territory for ACER-001, a proprietary powder formulation of sodium phenylbutyrate (NaPB) designed to be both taste-masked and immediate release for the treatment of Urea Cycle Disorders.